Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 0.85 |
| ▸ | JAK1 | P23458 | 3/20 | 0.85 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.85 |
| ▸ | RET | P07949 | 2/20 | 0.85 |
| ▸ | TYK2 | P29597 | 2/20 | 0.85 |
| ▸ | FLT3 | P36888 | 2/20 | 0.85 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.85 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.85 |
| ▸ | STK4 | Q13043 | 2/20 | 0.85 |
| ▸ | STK3 | Q13188 | 2/20 | 0.85 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.85 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.85 |
| ▸ | RPS6KA6 | Q9UK32 | 2/20 | 0.85 |
| ▸ | JAK2 | O60674 | 2/20 | 0.85 |
| ▸ | JAK3 | P52333 | 2/20 | 0.85 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.85 |
| ▸ | CSF1R | P07333 | 1/20 | 0.85 |
| ▸ | FLT4 | P35916 | 1/20 | 0.85 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.85 |
| ▸ | ITK | Q08881 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20734854 | 0.93 | SYK (0.85) | SYKJAK1CHEK1RETTYK2 | |
| Cerdulatinib SCHEMBL736734 | 0.92 | SYK (1.00) | SYKJAK1CHEK1RETTYK2 | |
| SCHEMBL21554052 | 0.92 | SYK (0.83) | SYKJAK1CHEK1RETTYK2 | |
| SCHEMBL8735647 | 0.92 | SYK (0.84) | SYKJAK1CHEK1RETTYK2 | |
| SCHEMBL21554086 | 0.91 | SYK (0.82) | SYKJAK1CHEK1RETTYK2 | |
| Cerdulatinib SCHEMBL29462019 | 0.91 | SYK (1.00) | SYKJAK1CHEK1RETTYK2 | |
| SCHEMBL22030443 | 0.90 | SYK (0.81) | SYKJAK1CHEK1RETTYK2 | |
| SCHEMBL21554054 | 0.89 | SYK (0.79) | SYKJAK1CHEK1RETTYK2 | |
| SCHEMBL23371373 | 0.89 | SYK (0.78) | SYKJAK1CHEK1RETTYK2 | |
| SCHEMBL19767559 | 0.88 | SYK (0.84) | SYKJAK1CHEK1RETTYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713309-B2 | Solid forms of Cerdulatinib | ALEXION PHARMACEUTICALS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20180186783-A1 | INHIBITORS OF PROTEIN KINASES | ALEXION PHARMACEUTICALS, INC. | 2018-07-05 | — | — | US | disclosed |
| US-20180147203-A1 | CERDULATINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES | ALEXION PHARMACEUTICALS, INC. | 2018-05-31 | — | — | US | disclosed |
| US-9868729-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170042896-A1 | CERDULATINIB FOR TREATING MYELOMA | ALEXION PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-8937070-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-01-20 | — | — | US | disclosed |
| US-20140031361-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. | 2014-01-30 | — | — | US | disclosed |
| US-20130237493-A1 | COMBINATION THERAPY OF 4-(CYCLOPROPYLAMINO)-2-(4-(4-(ETHYLSULFONYL)PIPERAZIN-1-YL)PHENYLAMINO)PYRIMIDINE-5-CARBOXAMIDE AND FLUDARABINE | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-8501944-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120129867-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129867-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK1 | SYK 1/4885JAK1 3/4885CHEK1 474/4885 |
| US-11713309-B2 | Solid forms of Cerdulatinib | CLK1, CLK2, DCLK1 | SYK 1096/4885JAK1 14/4885CHEK1 10/4885 |
| US-20180186783-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK1 | SYK 1/4885JAK1 3/4885CHEK1 474/4885 |
| US-20180147203-A1 | CERDULATINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES | BCL6B, BCL9, BCL9L | SYK 90/4885JAK1 86/4885CHEK1 176/4885 |
| US-20130237493-A1 | COMBINATION THERAPY OF 4-(CYCLOPROPYLAMINO)-2-(4-(4-(ETHYLSULFONYL)PIPERAZIN-1-YL)PHENYLAMINO)PYRIMIDINE-5-CARBOXAMIDE AND FLUDARABINE | BCL9, BCL9L, BCL6B | SYK 89/4885JAK1 391/4885CHEK1 2921/4885 |
| US-20170042896-A1 | CERDULATINIB FOR TREATING MYELOMA | MCL1, MYADM, BCL9 | SYK 2463/4885JAK1 565/4885CHEK1 323/4885 |
| US-20140031361-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK1 | SYK 1/4885JAK1 3/4885CHEK1 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.